Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?

J Clin Oncol. 2009 Apr 10;27(11):1919; author reply 1920-1. doi: 10.1200/JCO.2008.21.2951. Epub 2009 Mar 2.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Breast Neoplasms / secondary
  • Female
  • Genes, erbB-2
  • Humans
  • Lapatinib
  • Paclitaxel / administration & dosage
  • Quinazolines / administration & dosage

Substances

  • Quinazolines
  • Lapatinib
  • Paclitaxel